An-An Li1, Fan Li2, Min Lan3, Yu Zhang1, Dong Xie4, Mei-Ying Yan5. 1. Department of Orthopedic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China. 2. Ji'an College, Ji'an, Jiangxi, People's Republic of China. 3. Department of Orthopedic Surgery, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, People's Republic of China. 4. Department of Dermatology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China. 5. Medical Imaging Center, The Second Affiliated Hospital of Nanchang University, No. 1 Mingde Road, Donghu District, Nanchang, 330006, Jiangxi, People's Republic of China. 1471300271@qq.com.
Abstract
OBJECTIVE: Endoplasmic reticulum stress (ERS) and long non-coding RNAs (lncRNAs) are important in melanoma development and progression. This study aimed to explore the prognostic value of ERS-associated lncRNA profiles in cutaneous melanoma (CM). METHODS: The Cancer Genome Atlas (TCGA) provides the raw data of CM. GSEA website was used to obtain ERS-related genes, and mRNA and LncRNA co-expression network were used to obtain ERS-related lncRNAs. A Lasso regression analysis was used to identify a prognostic risk model for the composition of ERS-related lncRNAs. Patients were divided into high- and low-risk groups based on the model's risk score. The researchers then compared the two groups' survival rates, immune infiltration, chemotherapeutic drug sensitivity, and immune checkpoint gene expression. RESULTS: Thirty-nine ERS-related lncRNAs were discovered to be prognostic. A prognostic risk model made up of ten ERS-related lncRNAs was discovered. Patients in the low-risk group had a better prognosis than those in the high-risk group. An examination of tumor microenvironment revealed that risk scores correlated with immune cell infiltration in eight cases. Dacarbazine, paclitaxel, and cisplatin, three chemotherapy drugs, were more sensitive in the low-risk group than in the high-risk group. CONCLUSION: This study identified a risk model of ten ERS-related lncRNAs that have significant prognostic value in CM and could help guide clinical treatment.
OBJECTIVE: Endoplasmic reticulum stress (ERS) and long non-coding RNAs (lncRNAs) are important in melanoma development and progression. This study aimed to explore the prognostic value of ERS-associated lncRNA profiles in cutaneous melanoma (CM). METHODS: The Cancer Genome Atlas (TCGA) provides the raw data of CM. GSEA website was used to obtain ERS-related genes, and mRNA and LncRNA co-expression network were used to obtain ERS-related lncRNAs. A Lasso regression analysis was used to identify a prognostic risk model for the composition of ERS-related lncRNAs. Patients were divided into high- and low-risk groups based on the model's risk score. The researchers then compared the two groups' survival rates, immune infiltration, chemotherapeutic drug sensitivity, and immune checkpoint gene expression. RESULTS: Thirty-nine ERS-related lncRNAs were discovered to be prognostic. A prognostic risk model made up of ten ERS-related lncRNAs was discovered. Patients in the low-risk group had a better prognosis than those in the high-risk group. An examination of tumor microenvironment revealed that risk scores correlated with immune cell infiltration in eight cases. Dacarbazine, paclitaxel, and cisplatin, three chemotherapy drugs, were more sensitive in the low-risk group than in the high-risk group. CONCLUSION: This study identified a risk model of ten ERS-related lncRNAs that have significant prognostic value in CM and could help guide clinical treatment.
Authors: Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Larry D Dillon; Michael McPhee; Robert S Davidson; Ann P Quick; Brian Martin; Kyle R Covington; Olga Zolochevska; Robert W Cook; John T Vetto; Abel D Jarell; Martin D Fleming Journal: Curr Med Res Opin Date: 2022-02-15 Impact factor: 2.705
Authors: Roy M Bremnes; Lill-Tove Busund; Thomas L Kilvær; Sigve Andersen; Elin Richardsen; Erna Elise Paulsen; Sigurd Hald; Mehrdad Rakaee Khanehkenari; Wendy A Cooper; Steven C Kao; Tom Dønnem Journal: J Thorac Oncol Date: 2016-02-01 Impact factor: 15.609
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Michael B Atkins; Clara Curiel-Lewandrowski; David E Fisher; Susan M Swetter; Hensin Tsao; Julio A Aguirre-Ghiso; Maria S Soengas; Ashani T Weeraratna; Keith T Flaherty; Meenhard Herlyn; Jeffrey A Sosman; Hussein A Tawbi; Anna C Pavlick; Pamela B Cassidy; Sunandana Chandra; Paul B Chapman; Adil Daud; Zeynep Eroglu; Laura K Ferris; Bernard A Fox; Jeffrey E Gershenwald; Geoffrey T Gibney; Douglas Grossman; Brent A Hanks; Douglas Hanniford; Eva Hernando; Joanne M Jeter; Douglas B Johnson; Samir N Khleif; John M Kirkwood; Sancy A Leachman; Darren Mays; Kelly C Nelson; Vernon K Sondak; Ryan J Sullivan; Glenn Merlino Journal: Clin Cancer Res Date: 2021-01-07 Impact factor: 13.801